|
ES2452031T3
(es)
*
|
2006-02-03 |
2014-03-31 |
Eli Lilly & Company |
Compuestos y procedimientos para modular receptores FX
|
|
CL2007003035A1
(es)
*
|
2006-10-24 |
2008-05-16 |
Smithkline Beechman Corp |
Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
|
|
US7902201B2
(en)
|
2007-12-04 |
2011-03-08 |
Hoffmann-La Roche Inc. |
Isoxazolo-pyrazine derivatives
|
|
US7943619B2
(en)
|
2007-12-04 |
2011-05-17 |
Hoffmann-La Roche Inc. |
Isoxazolo-pyridazine derivatives
|
|
US7618973B2
(en)
|
2007-12-04 |
2009-11-17 |
Hoffmann-La Roche Inc. |
Isoxazolo-pyrazine derivatives
|
|
EP2367554A4
(en)
*
|
2008-11-26 |
2020-03-25 |
Satiogen Pharmaceuticals, Inc. |
Bile acid reflux inhibitor for the treatment of obesity and diabetes
|
|
TW201033201A
(en)
|
2009-02-19 |
2010-09-16 |
Hoffmann La Roche |
Isoxazole-isoxazole and isoxazole-isothiazole derivatives
|
|
US8389550B2
(en)
|
2009-02-25 |
2013-03-05 |
Hoffmann-La Roche Inc. |
Isoxazoles / O-pyridines with ethyl and ethenyl linker
|
|
US8222246B2
(en)
|
2009-04-02 |
2012-07-17 |
Hoffmann-La Roche Inc. |
Substituted isoxazoles
|
|
US8227461B2
(en)
|
2009-04-30 |
2012-07-24 |
Hoffmann-La Roche Inc. |
Isoxazoles
|
|
BRPI1014454A2
(pt)
|
2009-05-05 |
2016-04-05 |
Hoffmann La Roche |
derivados de isoxazol-pirazol
|
|
ES2601181T3
(es)
|
2009-05-05 |
2017-02-14 |
F. Hoffmann-La Roche Ag |
Derivados de isoxazol-tiazol como agonistas inversos del receptor GABA A para su uso en el tratamiento de trastornos cognitivos
|
|
US8415379B2
(en)
|
2009-05-05 |
2013-04-09 |
Hoffmann-La Roche Inc. |
Pyridines
|
|
BRPI1013762A2
(pt)
|
2009-05-05 |
2015-08-25 |
Hoffmann La Roche |
"derivados isoxazol-piridazina"
|
|
KR101354416B1
(ko)
|
2009-05-07 |
2014-02-19 |
에프. 호프만-라 로슈 아게 |
감마-아미노부티르산 조절제로서 이속사졸-피리딘 유도체
|
|
EP2289883A1
(en)
|
2009-08-19 |
2011-03-02 |
Phenex Pharmaceuticals AG |
Novel FXR (NR1H4) binding and activity modulating compounds
|
|
EP4137137A1
(en)
|
2010-05-26 |
2023-02-22 |
Satiogen Pharmaceuticals, Inc. |
Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
|
|
EP2545964A1
(en)
|
2011-07-13 |
2013-01-16 |
Phenex Pharmaceuticals AG |
Novel FXR (NR1H4) binding and activity modulating compounds
|
|
WO2013037482A1
(en)
|
2011-09-15 |
2013-03-21 |
Phenex Pharmaceuticals Ag |
Farnesoid x receptor agonists for cancer treatment and prevention
|
|
US8785435B2
(en)
|
2011-10-20 |
2014-07-22 |
Hoffmann-La Roche Inc. |
Solid forms
|
|
EA038594B1
(ru)
|
2011-10-28 |
2021-09-21 |
Шайр Хьюман Дженетик Терапис, Инк. |
Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени
|
|
JP6217938B2
(ja)
|
2011-10-28 |
2017-10-25 |
ルメナ ファーマシューティカルズ エルエルシー |
小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤
|
|
KR20160002773A
(ko)
|
2013-03-15 |
2016-01-08 |
루메나 파마수티컬즈, 인코포레이티드 |
원발성 담관염 및 염증성 장 질환 치료용 담즙산 재순환 억제제
|
|
AU2014229050A1
(en)
|
2013-03-15 |
2015-10-22 |
Lumena Pharmaceuticals Llc |
Bile acid recycling inhibitors for treatment of Barrett's esophagus and gastroesophageal reflux disease
|
|
MX377523B
(es)
|
2013-09-11 |
2025-03-10 |
Inst Nat Sante Rech Med |
Metodos y composiciones farmaceuticas para el tratamiento de la infeccion por el virus de la hepatitis b.
|
|
PE20160654A1
(es)
|
2013-11-22 |
2016-07-15 |
Pharmakea Inc |
Compuestos de inhibidor de autotaxina
|
|
CN104045635A
(zh)
*
|
2014-06-23 |
2014-09-17 |
华东理工大学 |
3,4,5-三取代异恶唑类化合物及其用途
|
|
EP3006939A1
(en)
|
2014-10-06 |
2016-04-13 |
Gilead Sciences, Inc. |
Histidine-rich Glycoprotein as a marker for hepatic Farnesoid X receptor activation
|
|
US10208081B2
(en)
|
2014-11-26 |
2019-02-19 |
Enanta Pharmaceuticals, Inc. |
Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
|
|
EP3034499A1
(en)
|
2014-12-17 |
2016-06-22 |
Gilead Sciences, Inc. |
Novel FXR (NR1H4) modulating compounds
|
|
EP3034501A1
(en)
|
2014-12-17 |
2016-06-22 |
Gilead Sciences, Inc. |
Hydroxy containing FXR (NR1H4) modulating compounds
|
|
TWI698430B
(zh)
|
2015-02-13 |
2020-07-11 |
南北兄弟藥業投資有限公司 |
三環化合物及其在藥物中的應用
|
|
RU2712099C2
(ru)
|
2015-03-31 |
2020-01-24 |
Энанта Фармасьютикалс, Инк. |
Производные желчных кислот в качестве агонистов fxr/tgr5 и способы их применения
|
|
CN107613986A
(zh)
*
|
2015-04-07 |
2018-01-19 |
英特塞普特医药品公司 |
用于组合疗法的药物组合物
|
|
CN116059203A
(zh)
*
|
2015-05-27 |
2023-05-05 |
赛博治疗有限责任公司 |
自分泌运动因子抑制剂及其用途
|
|
CN108602811B
(zh)
*
|
2016-02-01 |
2021-11-16 |
轩竹生物科技有限公司 |
Fxr受体激动剂
|
|
US10080741B2
(en)
|
2016-04-26 |
2018-09-25 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as FXR agonists and methods of use thereof
|
|
US10080743B2
(en)
|
2016-04-26 |
2018-09-25 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as FXR agonists and methods of use thereof
|
|
US10080742B2
(en)
|
2016-04-26 |
2018-09-25 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as FXR agonists and methods of use thereof
|
|
US10149835B2
(en)
|
2016-05-18 |
2018-12-11 |
Elmore Patent Law Group, P.C. |
Isoxazole derivatives as FXR agonists and methods of use thereof
|
|
WO2017201152A1
(en)
|
2016-05-18 |
2017-11-23 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as fxr agonists and methods of use thereof
|
|
US10144729B2
(en)
|
2016-05-18 |
2018-12-04 |
Enanta Pharmaceuticals, Inc. |
Isoxazole analogs as FXR agonists and methods of use thereof
|
|
MX2018014024A
(es)
*
|
2016-05-25 |
2019-08-29 |
Akarna Therapeutics Ltd |
Terapias de combinación con moduladores del receptor x farnesoide (fxr).
|
|
US10772813B2
(en)
|
2016-06-03 |
2020-09-15 |
Colradel, LLC |
Compositions and methods of administering a colchicine based topical composition for the prevention of radiation fibrosis
|
|
NZ748641A
(en)
|
2016-06-13 |
2020-04-24 |
Gilead Sciences Inc |
Fxr (nr1h4) modulating compounds
|
|
CA2968836C
(en)
|
2016-06-13 |
2025-09-02 |
Gilead Sciences, Inc. |
FXR MODULATING COMPOUNDS (NR1H4)
|
|
TW201808283A
(zh)
|
2016-08-05 |
2018-03-16 |
廣東東陽光藥業有限公司 |
含氮三環化合物及其在藥物中的應用
|
|
CA3039124A1
(en)
|
2016-10-04 |
2018-04-12 |
Enanta Pharmaceuticals, Inc. |
Isoxazole analogs as fxr agonists and methods of use thereof
|
|
WO2018081285A1
(en)
|
2016-10-26 |
2018-05-03 |
Enanta Pharmaceuticals, Inc. |
Urea-containing isoxazole derivatives as fxr agonists and methods of use thereof
|
|
ES2982801T3
(es)
|
2017-03-28 |
2024-10-17 |
Gilead Sciences Inc |
Combinaciones terapéuticas para el tratamiento de las enfermedades hepáticas
|
|
JP2020515564A
(ja)
|
2017-03-30 |
2020-05-28 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
エピソーマルウイルスの持続性及び発現を低下させるための方法及び医薬組成物
|
|
RU2741306C1
(ru)
|
2017-04-12 |
2021-01-25 |
Ил Дон Фармасьютикал Ко., Лтд. |
Производные изоксазола в качестве агонистов ядерных рецепторов и их применение
|
|
JP7212693B2
(ja)
|
2017-11-01 |
2023-01-25 |
ブリストル－マイヤーズ スクイブ カンパニー |
ファルネソイドｘ受容体モジュレーターとしての架橋二環化合物
|
|
CN111278821B
(zh)
|
2017-11-01 |
2023-10-03 |
百时美施贵宝公司 |
作为法尼醇x受体调节剂的螺环化合物
|
|
KR102731925B1
(ko)
|
2017-11-01 |
2024-11-18 |
브리스톨-마이어스 스큅 컴퍼니 |
파르네소이드 x 수용체 조정제로서의 멀티시클릭 화합물
|
|
US11168079B2
(en)
|
2017-11-01 |
2021-11-09 |
Bristol-Myers Squibb Company |
Alkene compounds as farnesoid x receptor modulators
|
|
US11286252B2
(en)
*
|
2017-11-01 |
2022-03-29 |
Bristol-Myers Squibb Company |
Alkene spirocyclic compounds as farnesoid X receptor modulators
|
|
US10689391B2
(en)
|
2017-12-12 |
2020-06-23 |
Enanta Pharmaceuticals, Inc. |
Isoxazole analogs as FXR agonists and methods of use thereof
|
|
CN110128432B
(zh)
|
2018-02-02 |
2021-03-02 |
广东东阳光药业有限公司 |
含氮三环化合物及其在药物中的应用
|
|
WO2019160813A1
(en)
|
2018-02-14 |
2019-08-22 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as fxr agonists and methods of use thereof
|
|
KR102692309B1
(ko)
|
2019-01-15 |
2024-08-07 |
길리애드 사이언시즈, 인코포레이티드 |
Fxr (nr1h4) 조정 화합물
|
|
EP4424363B1
(en)
|
2019-02-12 |
2026-04-29 |
Mirum Pharmaceuticals, Inc. |
Methods for increasing growth in pediatric subjects having cholestatic liver disease
|
|
US12319676B2
(en)
|
2019-02-15 |
2025-06-03 |
Bristol-Myers Squibb Company |
Substituted amide compounds useful as farnesoid X receptor modulators
|
|
JP7449300B2
(ja)
|
2019-02-15 |
2024-03-13 |
ブリストル－マイヤーズ スクイブ カンパニー |
ファルネソイドｘ受容体モジュレータとして有用な置換アミド化合物
|
|
AR118050A1
(es)
|
2019-02-15 |
2021-09-15 |
Bristol Myers Squibb Co |
Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x
|
|
JP7465883B2
(ja)
|
2019-02-15 |
2024-04-11 |
ブリストル－マイヤーズ スクイブ カンパニー |
ファルネソイドｘ受容体モジュレータとしての置換二環式化合物
|
|
WO2020172075A1
(en)
|
2019-02-19 |
2020-08-27 |
Gilead Sciences, Inc. |
Solid forms of fxr agonists
|
|
WO2020231917A1
(en)
|
2019-05-13 |
2020-11-19 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as fxr agonists and methods of use thereof
|
|
WO2021009332A1
(en)
|
2019-07-18 |
2021-01-21 |
Enyo Pharma |
Method for decreasing adverse-effects of interferon
|
|
WO2021108974A1
(en)
|
2019-12-03 |
2021-06-10 |
Gannex Pharma Co., Ltd |
Compounds for modulating activity of fxr and uses thereof
|
|
IL293892A
(en)
|
2020-01-15 |
2022-08-01 |
Inserm Institut National De La Sant? Et De La Rech M?Dicale |
Use of fxr agonists for treating an infection by hepatitis d virus
|
|
MX2023008365A
(es)
|
2021-01-14 |
2023-10-04 |
Enyo Pharma |
Efecto sinérgico de un agonista de fxr e ifn para el tratamiento de infección por hbv.
|
|
TW202308629A
(zh)
|
2021-04-28 |
2023-03-01 |
法商Ｅｎｙｏ製藥公司 |
使用fxr激動劑作為組合治療以增強tlr3激動劑之療效
|